United Therapeutics CEO Martine A. Rothblatt disposes of shares worth $4,287,172.85

By Public Technologies
  • United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercise and stock sales on Sept. 29, 2026.
  • Family trust acquired 9,500 shares at USD 117.76 via stock option exercise.
  • Trust sold 9,500 shares at prices from USD 472.0452 to USD 486.77.
  • Trust-held common stock position ended at 324,443 shares.
  • Trust-held stock options ended at 337,910 options, exercisable at USD 117.76.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000152), on September 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk